Diversified Trust Co lifted its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 16.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,622 shares of the life sciences company’s stock after acquiring an additional 2,605 shares during the period. Diversified Trust Co’s holdings in Integra Lifesciences were worth $1,040,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the stock. Champlain Investment Partners LLC raised its position in Integra Lifesciences by 1.4% in the 1st quarter. Champlain Investment Partners LLC now owns 5,473,820 shares of the life sciences company’s stock worth $305,001,000 after purchasing an additional 77,845 shares during the period. Janus Henderson Group PLC raised its position in Integra Lifesciences by 31.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,873,324 shares of the life sciences company’s stock worth $160,102,000 after purchasing an additional 688,761 shares during the period. Clearbridge Investments LLC raised its position in Integra Lifesciences by 21.2% in the 1st quarter. Clearbridge Investments LLC now owns 2,442,164 shares of the life sciences company’s stock worth $136,077,000 after purchasing an additional 426,578 shares during the period. Vaughan Nelson Investment Management L.P. raised its position in Integra Lifesciences by 26.1% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock worth $61,860,000 after purchasing an additional 230,010 shares during the period. Finally, Geode Capital Management LLC raised its position in Integra Lifesciences by 5.7% in the 4th quarter. Geode Capital Management LLC now owns 731,431 shares of the life sciences company’s stock worth $32,987,000 after purchasing an additional 39,637 shares during the period. 82.20% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently weighed in on the stock. Wells Fargo & Co reissued an “outperform” rating and issued a $135.00 price objective (up from $120.00) on shares of Paypal in a research report on Thursday. Zacks Investment Research raised shares of Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. JMP Securities raised their target price on shares of Integra Lifesciences to $75.00 in a research report on Thursday. Finally, ValuEngine raised shares of United States Steel from a “strong sell” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $61.00.
Shares of NASDAQ:IART traded up $0.08 during trading on Thursday, reaching $63.30. 14,508 shares of the company were exchanged, compared to its average volume of 423,908. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 1.67 and a beta of 1.07. The business’s fifty day simple moving average is $53.28. Integra Lifesciences Holdings Corp has a 12-month low of $42.14 and a 12-month high of $66.41. The company has a quick ratio of 1.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.95.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.07. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The firm had revenue of $383.60 million for the quarter, compared to the consensus estimate of $373.29 million. During the same period last year, the firm earned $0.60 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. On average, sell-side analysts expect that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current fiscal year.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: What is a death cross?
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.